Irtoaako tästä jotain uutta infoa? BONO linkkarissa:
Breaking mmunotherapy resistance—Blaze trial to start🔥
Huge thanks to Dr. Anna Minchom for persistence. BEXMAB trial in AML and MDS has shown that bexmarilimab (BEX) is an ideal backbone for combination treatments, and now we’re moving that momentum into solid tumours. First up: the Blaze trial at The Institute of Cancer Research in partnership with The Royal Marsden, combining bexmarilimab + anti‑PD‑1 (zimberelimab) to re‑sensitize patients with metastatic NSCLC and melanoma who have progressed within 12 weeks of the last dose of immune checkpoint therapy.
This is a logical next step after the MATINS first‑in‑human study, where single‑agent bexmarilimab delivered disease control and Anna played a key role as investigator. In this BLAZE proof-of-concept study, metastatic NSCLC and melanoma patients exhibiting secondary resistance to immune checkpoint inhibitors are treated with bexmarilimab + zimberelimab.
Breaking immunotherapy resistance starts here!